The Cancer Letter

Inside information on cancer research and drug development

In Brief

Albert Einstein College of Medicine enters agreement with Jiangsu Hengrui Medicine

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

ALBERT EINSTEIN COLLEGE OF MEDICINE entered into a research agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop innovative cancer therapies. The collaboration is the first between Einstein and a pharmaceutical company based in China.

Jiangsu Hengrui Medicine, established in 1970, is a fully integrated pharmaceutical company with annual net sales of over $1.2 billion. Hengrui’s products and research span therapeutic areas including oncology and hematology, anesthesiology and pain management, cardiovascular and metabolic diseases, contrast media and inflammation.

Table of Contents

YOU MAY BE INTERESTED IN

AACR progress report highlights AI’s role in research and clinical care
Obstacles to progress include systemic disparities and dwindling appropriations

Artificial intelligence is starting to transform life sciences by accelerating drug discovery and development, optimizing clinical trials, and creating personalized treatments for cancer patients, speakers said at the Sept. 18 unveiling of the American Association for Cancer Research 2024 Cancer Progress Report. 
By McKenzie Prillaman
Table of Contents

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.
COMPLETE OUR SURVEY

Login

Site license subscribers:
Log in with your IP | Register a sponsored account